MetaCap

Fortress Biotech (FBIO) vs Rani Therapeutics (RANI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fortress Biotech (FBIO) has outperformed Rani Therapeutics (RANI) over the past year, losing 26.6% versus a loss of 68.6%. Over five years, FBIO leads with a -95.5% price change compared with -98.3% for RANI. Fortress Biotech is the larger company by market cap ($64.1 million vs $59.0 million), about 1.1 times the size, while Rani Therapeutics is growing revenue faster (+58.9% vs +9.7%).

Fortress Biotech converts more of its revenue into profit, with a net margin of 10.8% versus -1817.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FBIO-26.64%RANI-68.64%
+76%+0%-76%
Nov 21, 20251 yearNov 20, 2026
FBIO-95.90%RANI-98.50%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FBIO versus RANI key metrics
MetricFBIORANI
Share price$1.90$0.5111
Market cap$64.11M$59.03M
1-day change+7.34%-11.97%
YTD return-48.09%-62.14%
1-year return-26.64%-68.64%
5-year return-95.52%-98.34%
P/E ratio (TTM)0.83—
EPS (TTM)$2.30$-0.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.26M$1.63M
Revenue growth (YoY)+9.69%+58.85%
Net income (latest FY)$6.82M$-29.67M
Gross margin66.92%—
Operating margin-111.00%-2345.99%
Net margin10.77%-1817.09%
52-week high$4.53$1.69
52-week low$1.64$0.502
Distance from 52-week high-58.06%-69.76%
Analyst consensusnonestrong_buy
Avg. price target upside+163.16%+1308.73%
Average volume281.49K545.67K
Shares outstanding33.74M115.49M
Employees7869
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FBIO has outperformed RANI by 42.0 percentage points over the past year.
  • Fortress Biotech is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -1817.1 cents for Rani Therapeutics.
  • Rani Therapeutics grew revenue faster in its latest fiscal year (+58.85% vs +9.69%).

About Fortress Biotech

FBIO stock →

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees

About Rani Therapeutics

RANI stock →

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

FBIO vs RANI FAQ

Which is bigger, Fortress Biotech or Rani Therapeutics?

Fortress Biotech (FBIO) is larger, with a market capitalization of $64.11M compared with $59.03M for Rani Therapeutics (RANI).

Which stock has performed better over the past year, FBIO or RANI?

FBIO returned -26.64% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.

Are Fortress Biotech and Rani Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons